← Back to Search

Radiation Therapy

Stereotactic Radiosurgery using NovalisTx for Prostate Cancer

Phase 1
Waitlist Available
Led By P. Brian Volpp, MD, MPH
Research Sponsored by San Diego Radiosurgery
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer. The investigators will gather scientific information about the tolerance and side effects this type of radiation. The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic Radiosurgery using NovalisTxExperimental Treatment1 Intervention
Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.

Find a Location

Who is running the clinical trial?

San Diego RadiosurgeryLead Sponsor
P. Brian Volpp, MD, MPHPrincipal InvestigatorSan Diego Radiosurgery/X-Ray Medical Group-Radiation Oncology
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top